Windtree Therapeutics Inc Share Price Today: Live Updates & Key Insights
Windtree Therapeutics Inc share price today is $0.1001, up -77.21%. The stock opened at $0.483 against the previous close of $0.4827, with an intraday high of $0.4845 and low of $0.1005.
Windtree Therapeutics Inc Share Price Chart
Windtree Therapeutics Inc
Windtree Therapeutics Inc Share Price Performance
Windtree Therapeutics Inc Institutional Holdings
Windtree Therapeutics Inc Market Status
Windtree Therapeutics Inc Fundamentals
Market Cap 13.83 M
PB Ratio 1.3444
PE Ratio 0.0
Enterprise Value 14.24 M
Total Assets 27.88 M
Volume 48688870
Windtree Therapeutics Inc Company Financials
About Windtree Therapeutics Inc & investment objective
Company Information Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Organisation Biotechnology
Employees 14
Industry Biotechnology
CEO Mr. Jed A. Latkin
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
